OMNY Health expands real-world data network with over 300 clinical measures to support disease research

OMNY Health has added more than 300 new clinical assessment measures to its national real-world data (RWD) platform, aiming to improve disease tracking, treatment evaluation, and evidence generation across key medical specialties.

The newly added measures provide a more structured and detailed view of patient health, enabling researchers and healthcare organizations to better assess disease progression and treatment outcomes. These include established clinical tools such as the Crohn’s Disease Activity Index (CDAI), the Harvey Bradshaw index for Gastroenterology, Asthma Control Test, and COPD Assessment Test. Derived from both structured and unstructured electronic health records (EHRs) data, the measures support research across dermatology, respiratory, cardiovascular, autoimmune, gastroenterology, neurology, and oncology.

OMNY Health initially applied this approach in dermatology and is now expanding its use of disease-specific clinical measures across multiple specialties. The company’s national data network currently includes information on more than 85 million patients, drawn from over 500,000 providers and 200 clinical specialties.

“By leveling up research and making more information available across multiple specialties, OMNY Health enables teams to fill information gaps, accelerate research timelines, and make meaningful improvements to patient care,” said Dr Mitesh Rao, CEO and Co-Founder of OMNY Health.

Rao explained that much of the meaningful insight in healthcare data is locked away in unstructured sources:

“A lot of the real insight in healthcare data is often buried in the unstructured data,” he said. “OMNY has gone that additional mile now and for all these therapeutic areas, we're actually curating out disease-specific measures that include things like clinical severity indicators, surveys, questionnaires.” He added that, “this is the first time you're really going to see that level of scale and depth tied to such a large national repository of data.”

The expanded dataset aims to provide a more complete picture of patient health and supports longitudinal tracking of clinical outcomes, quality of life, and healthcare utilization.

“If I were to summarize what this kind of data set could do, it is to provide a very granular patient journey on a patient level, both in terms of clinical outcome — what happened to them — the quality of life, and also the cost journey of a particular patient,” said Dr TY Alvin Liu, Inaugural Director of the James P Gills Jr MD and Heather Gills Artificial Intelligence Innovation Center at Johns Hopkins Medicine. “The combination of costs and outcomes on an individual level, in a longitudinal manner, it just makes it so powerful.”

Liu also highlighted the system-level benefits: “By taking previously untapped data sources and turning them into resources for better care, we can provide more precise and accurate treatments to patients across care specialties and unparalleled insights for executives to make decisions on a system level.”

The expansion follows OMNY Health’s announcement earlier this year that its platform had processed more than 4 billion unstructured clinical notes. According to Rao,

“Historically, you'd need thousands of chart abstractors sitting there manually combing through data… Now you have large language models that can actually do some of this at scale and can enable finding those pieces.”